The relationships between plasma and erythrocyte antioxidant enzymes and lipid peroxidation in patients with rheumatoid arthritis

Basit Öğe Kaydı
dc.authorscopusid7006625363
dc.authorscopusid6507147136
dc.authorscopusid6602609706
dc.authorscopusid7003693574
dc.authorscopusid6603551686
dc.authorscopusid15747548500
dc.authorscopusid7004682700
dc.contributor.authorAkyol Ö.
dc.contributor.authorIşçi N.
dc.contributor.authorTemel I.
dc.contributor.authorÖzgöçmen S.
dc.contributor.authorUz E.
dc.contributor.authorMurat M.
dc.contributor.authorBüyükberber S.
dc.date.accessioned2024-08-04T20:00:49Z
dc.date.available2024-08-04T20:00:49Z
dc.date.issued2001
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective. The present study was undertaken to evaluate the activities of some key erythrocyte and plasma enzymes participating in free radical metabolism and the end product of lipid peroxidation in rheumatoid arthritis, and whether there are any differences for these parameters between newly diagnosed untreated patients and rheumatoid arthritis patients on drug therapy. Patients and methods. Superoxide dismutase and catalase activities, and malondialdehyde levels were determined in erythrocytes and plasma samples from 54 patients with rheumatoid arthritis (21 of whom without any treatment and 33 on classical therapy regimens) and from 33 healthy controls. Results. There were no statistically significant differences in mean values of activities of the erythrocyte enzymes between the patients and controls. Malondialdehyde levels were significantly increased in both newly diagnosed untreated patients and patients on drug therapy compared to control subjects. Malondialdehyde levels were lower in the treated group than the newly diagnosed untreated group (0.214 ± 0.111 ?mol/L and 0.388 ± 0.075 ?mol/L, respectively) (P < 0.0001). Mean plasma superoxide dismutase activity was lower in the group of newly diagnosed untreated patients compared to those of the treated and control groups (1.31 ± 0.069 U/mL, 1.79 ± 0.94 U/mL and 2.48 ± 0.94 U/mL, respectively) (P < 0.0001, untreated vs control groups). Conclusions. These results suggest sufficient antioxidant enzyme activities in erythrocytes in patients with rheumatoid arthritis and also increased lipid peroxidation end products in newly diagnosed untreated patients compared to control group and patients on drug therapy. © 2001 Éditions scientifiques et médicales Elsevier SAS.en_US
dc.identifier.doi10.1016/S1169-8330(01)00151-X
dc.identifier.endpage608en_US
dc.identifier.issn1169-8330
dc.identifier.issue7en_US
dc.identifier.scopus2-s2.0-0035724999en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage601en_US
dc.identifier.urihttps://doi.org/10.1016/S1169-8330(01)00151-X
dc.identifier.urihttps://hdl.handle.net/11616/91034
dc.identifier.volume68en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Masson SASen_US
dc.relation.ispartofRevue du Rhumatisme (Edition Francaise)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCatalaseen_US
dc.subjectMalondialdehydeen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectSuperoxide dismutaseen_US
dc.titleThe relationships between plasma and erythrocyte antioxidant enzymes and lipid peroxidation in patients with rheumatoid arthritisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu